The HAT/HDAC interplay: Multilevel control of STAT signaling

Cytokine and Growth Factor Reviews

Volumn 23, Issue 6, 2012, Pages 283-291

  Icardi, Laura ^a,b   De Bosscher, Karolien ^a,b   Tavernier, Jan ^a,b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

Acetylation; HAT; HDAC; Signal transduction; STAT; Transcriptional regulation

Indexed keywords

AR 42; BUTYRIC ACID; CISPLATIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; ENTINOSTAT; GAMMA INTERFERON; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE GCN5; HISTONE ACETYLTRANSFERASE PCAF; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; TAMOXIFEN; TRANSCRIPTION FACTOR SIN3A; TRICHOSTATIN A; UNCLASSIFIED DRUG; VORINOSTAT;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; CELL SPECIFICITY; DEACETYLATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ACETYLATION; HISTONE ACETYLTRANSFERASES; HISTONE DEACETYLASES; HUMANS; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84869874931     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2012.08.002     Document Type: Short Survey

References (93)

1. Stark G.R., Darnell J.E. The JAK-STAT pathway at twenty. Immunity 2012, 36:503-514.
2. Lee K.K., Workman J.L. Histone acetyltransferase complexes: one size doesn't fit all. Nature Reviews Molecular Cell Biology 2007, 8:284-295.
3. Shahbazian M.D., Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annual Review of Biochemistry 2007, 76:75-100.
4. Akimova T., Beier U.H., Liu Y., Wang L., Hancock W.W. Histone/protein deacetylases and T-cell immune responses. Blood 2012, 119:2443-2451.
5. Spange S., Wagner T., Heinzel T., Kramer O.H. Acetylation of non-histone proteins modulates cellular signalling at multiple levels. International Journal of Biochemistry and Cell Biology 2009, 41:185-198.
6. Nusinzon I., Horvath C.M. Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Science's STKE 2005, 2005:re11.
7. Paulson M., Press C., Smith E., Tanese N., Levy D.E. IFN-stimulated transcription through a TBP-free acetyltransferase complex escapes viral shutoff. Nature Cell Biology 2002, 4:140-147.
8. Korzus E., Torchia J., Rose D.W., Xu L., Kurokawa R., McInerney E.M., et al. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. Science 1998, 279:703-707.
9. Brierley M.M., Fish E.N. Stats: multifaceted regulators of transcription. Journal of Interferon and Cytokine Research 2005, 25:733-744.
10. Wojciak J.M., Martinez-Yamout M.A., Dyson H.J., Wright P.E. Structural basis for recruitment of CBP/p300 coactivators by STAT1 and STAT2 transactivation domains. EMBO Journal 2009, 28:948-958.
11. Zhang J.J., Vinkemeier U., Gu W., Chakravarti D., Horvath C.M., Darnell J.E. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:15092-15096.
12. Ramos Y.F., Hestand M.S., Verlaan M., Krabbendam E., Ariyurek Y., van Galen M., et al. Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Research 2010, 38:5396-5408.
13. McDonald C., Reich N.C. Cooperation of the transcriptional coactivators CBP and p300 with Stat6. Journal of Interferon and Cytokine Research 1999, 19:711-722.
14. Bhattacharya S., Eckner R., Grossman S., Oldread E., Arany Z., D'Andrea A., et al. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. Nature 1996, 383:344-347.
15. Ray S., Sherman C.T., Lu M., Brasier A.R. Angiotensinogen gene expression is dependent on signal transducer and activator of transcription 3-mediated p300/cAMP response element binding protein-binding protein coactivator recruitment and histone acetyltransferase activity. Molecular Endocrinology 2002, 16:824-836.
16. Pfitzner E., Jahne R., Wissler M., Stoecklin E., Groner B. p300/CREB-binding protein enhances the prolactin-mediated transcriptional induction through direct interaction with the transactivation domain of Stat5, but does not participate in the Stat5-mediated suppression of the glucocorticoid response. Molecular Endocrinology 1998, 12:1582-1593.
17. Tang X., Gao J.S., Guan Y.J., McLane K.E., Yuan Z.L., Ramratnam B., et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007, 131:93-105.
18. Kramer O.H., Knauer S.K., Greiner G., Jandt E., Reichardt S., Guhrs K.H., et al. A phosphorylation-acetylation switch regulates STAT1 signaling. Genes and Development 2009, 23:223-235.
19. Ma L., Gao J.S., Guan Y., Shi X., Zhang H., Ayrapetov M.K., et al. Acetylation modulates prolactin receptor dimerization. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:19314-19319.
20. Kouzarides T. Chromatin modifications and their function. Cell 2007, 128:693-705.
21. Cudejko C., Wouters K., Fuentes L., Hannou S.A., Paquet C., Bantubungi K., et al. p16INK4a deficiency promotes IL-4-induced polarization and inhibits proinflammatory signaling in macrophages. Blood 2011, 118:2556-2566.
22. Kramer O.H., Baus D., Knauer S.K., Stein S., Jager E., Stauber R.H., et al. Acetylation of Stat1 modulates NF-kappaB activity. Genes and Development 2006, 20:473-485.
23. Stronach E.A., Alfraidi A., Rama N., Datler C., Studd J.B., Agarwal R., et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Research 2011, 71:4412-4422.
24. Guo L., Guo H., Gao C., Mi Z., Russell W.B., Kuo P.C. Stat1 acetylation inhibits inducible nitric oxide synthase expression in interferon-gamma-treated RAW264.7 murine macrophages. Surgery 2007, 142:156-162.
25. Mertens C., Zhong M., Krishnaraj R., Zou W., Chen X., Darnell J.E. Dephosphorylation of phosphotyrosine on STAT1 dimers requires extensive spatial reorientation of the monomers facilitated by the N-terminal domain. Genes and Development 2006, 20:3372-3381.
26. Kramer O.H., Heinzel T. Phosphorylation-acetylation switch in the regulation of STAT1 signaling. Molecular and Cellular Endocrinology 2010, 315:40-48.
27. Antunes F., Marg A., Vinkemeier U. STAT1 signaling is not regulated by a phosphorylation-acetylation switch. Molecular and Cellular Biology 2011, 31:3029-3037.
28. Jain S., Wei J., Mitrani L.R., Bishopric N.H. Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival. Breast Cancer Research and Treatment 2012, 135:103-114.
29. Yuan Z.L., Guan Y.J., Chatterjee D., Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307:269-273.
30. Wang R., Cherukuri P., Luo J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. Journal of Biological Chemistry 2005, 280:11528-11534.
31. Nie Y., Erion D.M., Yuan Z., Dietrich M., Shulman G.I., Horvath T.L., et al. STAT3 inhibition of gluconeogenesis is downregulated by SirT1. Nature Cell Biology 2009, 11:492-500.
32. Sestito R., Madonna S., Scarponi C., Cianfarani F., Failla C.M., Cavani A., et al. STAT3-dependent effects of IL-22 in human keratinocytes are counterregulated by sirtuin 1 through a direct inhibition of STAT3 acetylation. FASEB Journal 2011, 25:916-927.
33. 2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology 2005, 129:1616-1632.
34. 2-terminal domain stabilizes enhanceosome assembly by interacting with the p300 bromodomain. Journal of Biological Chemistry 2008, 283:30725-30734.
35. Ray S., Lee C., Hou T., Boldogh I., Brasier A.R. Requirement of histone deacetylase1 (HDAC1) in signal transducer and activator of transcription 3 (STAT3) nucleocytoplasmic distribution. Nucleic Acids Research 2008, 36:4510-4520.
36. Van Nguyen T., Angkasekwinai P., Dou H., Lin F.M., Lu L.S., Cheng J., et al. SUMO-specific protease 1 is critical for early lymphoid development through regulation of STAT5 activation. Molecular Cell 2012, 45:210-221.
37. Chang S., Aune T.M. Histone hyperacetylated domains across the Ifng gene region in natural killer cells and T cells. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:17095-17100.
38. Avni O., Lee D., Macian F., Szabo S.J., Glimcher L.H., Rao A. T(H) cell differentiation is accompanied by dynamic changes in histone acetylation of cytokine genes. Nature Immunology 2002, 3:643-651.
39. Fields P.E., Kim S.T., Flavell R.A. Cutting edge: changes in histone acetylation at the IL-4 and IFN-gamma loci accompany Th1/Th2 differentiation. Journal of Immunology 2002, 169:647-650.
40. Lim B.O. Coriolus versicolor suppresses inflammatory bowel disease by Inhibiting the expression of STAT1 and STAT6 associated with IFN-gamma and IL-4 expression. Phytotherapy Research 2011, 25:1257-1261.
41. Shankaranarayanan P., Chaitidis P., Kuhn H., Nigam S. Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. Journal of Biological Chemistry 2001, 276:42753-42760.
42. Ungureanu D., Vanhatupa S., Gronholm J., Palvimo J.J., Silvennoinen O. SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood 2005, 106:224-226.
43. Latham J.A., Dent S.Y. Cross-regulation of histone modifications. Nature Structural & Molecular Biology 2007, 14:1017-1024.
44. Benayoun B.A., Veitia R.A. A post-translational modification code for transcription factors: sorting through a sea of signals. Trends in Cell Biology 2009, 19:189-197.
45. Yang X.J., Seto E. Lysine acetylation: codified crosstalk with other posttranslational modifications. Molecular Cell 2008, 31:449-461.
46. Schuringa J.J., Schepers H., Vellenga E., Kruijer W. Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation. FEBS Letters 2001, 495:71-76.
47. Ramsauer K., Farlik M., Zupkovitz G., Seiser C., Kroger A., Hauser H., et al. Distinct modes of action applied by transcription factors STAT1 and IRF1 to initiate transcription of the IFN-gamma-inducible gbp2 gene. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:2849-2854.
48. Ginter T., Bier C., Knauer S.K., Sughra K., Hildebrand D., Munz T., et al. Histone deacetylase inhibitors block IFNgamma-induced STAT1 phosphorylation. Cellular Signalling 2012, 24:1453-1460.
49. Ohbayashi N., Ikeda O., Taira N., Yamamoto Y., Muromoto R., Sekine Y., et al. LIF- and IL-6-induced acetylation of STAT3 at Lys-685 through PI3K/Akt activation. Biological and Pharmaceutical Bulletin 2007, 30:1860-1864.
50. Wilson B.G., Roberts C.W. SWI/SNF nucleosome remodellers and cancer. Nature Reviews Cancer 2011, 11:481-492.
51. Chi T. A BAF-centred view of the immune system. Nature Reviews Immunology 2004, 4:965-977.
52. Ni Z., Karaskov E., Yu T., Callaghan S.M., Der S., Park D.S., et al. Apical role for BRG1 in cytokine-induced promoter assembly. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:14611-14616.
53. Cui K., Tailor P., Liu H., Chen X., Ozato K., Zhao K. The chromatin-remodeling BAF complex mediates cellular antiviral activities by promoter priming. Molecular and Cellular Biology 2004, 24:4476-4486.
54. Ni Z., Bremner R. Brahma-related gene 1-dependent STAT3 recruitment at IL-6-inducible genes. Journal of Immunology 2007, 178:345-351.
55. Huang M., Qian F., Hu Y., Ang C., Li Z., Wen Z. Chromatin-remodelling factor BRG1 selectively activates a subset of interferon-alpha-inducible genes. Nature Cell Biology 2002, 4:774-781.
56. Zhang Y., Cheng M.B., Zhang Y.J., Zhong X., Dai H., Yan L., et al. A switch from hBrm to Brg1 at IFNgamma-activated sequences mediates the activation of human genes. Cell Research 2010, 20:1345-1360.
57. Lang C., Hildebrandt A., Brand F., Opitz L., Dihazi H., Luder C.G. Impaired chromatin remodelling at STAT1-regulated promoters leads to global unresponsiveness of Toxoplasma gondii-infected macrophages to IFN-gamma. PLoS Pathogens 2012, 8:e1002483.
58. Lim E.J., Lu T.X., Blanchard C., Rothenberg M.E. Epigenetic regulation of the IL-13-induced human eotaxin-3 gene by CREB-binding protein-mediated histone 3 acetylation. Journal of Biological Chemistry 2011, 286:13193-13204.
59. Shi M., Lin T.H., Appell K.C., Berg L.J. Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 2008, 28:763-773.
60. Vlasakova J., Novakova Z., Rossmeislova L., Kahle M., Hozak P., Hodny Z. Histone deacetylase inhibitors suppress IFNalpha-induced up-regulation of promyelocytic leukemia protein. Blood 2007, 109:1373-1380.
61. Sakamoto S., Potla R., Larner A.C. Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. Journal of Biological Chemistry 2004, 279:40362-40367.
62. Nusinzon I., Horvath C.M. Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:14742-14747.
63. Chang H.M., Paulson M., Holko M., Rice C.M., Williams B.R., Marie I., et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:9578-9583.
64. Klampfer L., Huang J., Swaby L.A., Augenlicht L. Requirement of histone deacetylase activity for signaling by STAT1. Journal of Biological Chemistry 2004, 279:30358-30368.
65. Sebastian C., Serra M., Yeramian A., Serrat N., Lloberas J., Celada A. Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. Journal of Immunology 2008, 180:5898-5906.
66. Xu M., Nie L., Kim S.H., Sun X.H. STAT5-induced Id-1 transcription involves recruitment of HDAC1 and deacetylation of C/EBPbeta. EMBO Journal 2003, 22:893-904.
67. Koyama Y., Adachi M., Sekiya M., Takekawa M., Imai K. Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood 2000, 96:1490-1495.
68. Inks E.S., Josey B.J., Jesinkey S.R., Chou C.J. A novel class of small molecule inhibitors of HDAC6. ACS Chemical Biology 2012, 7:331-339.
69. Buglio D., Georgakis G.V., Hanabuchi S., Arima K., Khaskhely N.M., Liu Y.J., et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008, 112:1424-1433.
70. Gupta M., Han J.J., Stenson M., Wellik L., Witzig T.E. Regulation of STAT3 by histone deacetylase-3 in diffuse large B-cell lymphoma: implications for therapy. Leukemia 2011, 26:1356-1364.
71. Pang M., Ma L., Liu N., Ponnusamy M., Zhao T.C., Yan H., et al. Histone deacetylase 1/2 mediates proliferation of renal interstitial fibroblasts and expression of cell cycle proteins. Journal of Cellular Biochemistry 2011, 112:2138-2148.
72. Pang M., Kothapally J., Mao H., Tolbert E., Ponnusamy M., Chin Y.E., et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. American Journal of Physiology. Renal Physiology 2009, 297:F996-F1005.
73. Lin T.Y., Fenger J., Murahari S., Bear M.D., Kulp S.K., Wang D., et al. AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated kit. Blood 2010, 115:4217-4225.
74. Xiong H., Du W., Zhang Y.J., Hong J., Su W.Y., Tang J.T., et al. Trichostatin A, a histone deacetylase inhibitor, suppresses JAK2/STAT3 signaling via inducing the promoter-associated histone acetylation of SOCS1 and SOCS3 in human colorectal cancer cells. Molecular Carcinogenesis 2012, 51:174-184.
75. Silverstein R.A., Ekwall K. Sin3: a flexible regulator of global gene expression and genome stability. Current Genetics 2005, 47:1-17.
76. Dannenberg J.H., David G., Zhong S., van der Torre J., Wong W.H., Depinho R.A. mSin3A corepressor regulates diverse transcriptional networks governing normal and neoplastic growth and survival. Genes and Development 2005, 19:1581-1595.
77. Torres L., Sandoval J., Penella E., Zaragoza R., Garcia C., Rodriguez J.L., et al. In vivo GSH depletion induces c-myc expression by modulation of chromatin protein complexes. Free Radical Biology and Medicine 2009, 46:1534-1542.
78. Cheng P.Y., Lin Y.P., Chen Y.L., Lee Y.C., Tai C.C., Wang Y.T., et al. Interplay between SIN3A and STAT3 mediates chromatin conformational changes and GFAP expression during cellular differentiation. PLoS One 2011, 6:e22018.
79. Icardi L., Mori R., Gesellchen V., Eyckerman S., De Cauwer L., Verhelst J., et al. The Sin3a repressor complex is a master regulator of STAT transcriptional activity. Proceedings of the National Academy of Sciences of the United States of America 2012.
80. Icardi L., Lievens S., Mori R., Piessevaux J., De Cauwer L., De Bosscher K., et al. Opposed regulation of type I IFN-induced STAT3 and ISGF3 transcriptional activities by histone deacetylases (HDACS) 1 and 2. FASEB Journal 2012, 26:240-249.
81. Regis G., Icardi L., Conti L., Chiarle R., Piva R., Giovarelli M., et al. IL-6, but not IFN-gamma, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing. Leukemia 2009, 23:2102-2108.
82. Dong L., Zhang X., Fu X., Gao X., Zhu M., Wang X., et al. PTB-associated splicing factor (PSF) functions as a repressor of STAT6-mediated Ig epsilon gene transcription by recruitment of HDAC1. Journal of Biological Chemistry 2011, 286:3451-3459.
83. Mathur M., Tucker P.W., Samuels H.H. PSF is a novel corepressor that mediates its effect through Sin3A and the DNA binding domain of nuclear hormone receptors. Molecular and Cellular Biology 2001, 21:2298-2311.
84. Rascle A., Johnston J.A., Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Molecular and Cellular Biology 2003, 23:4162-4173.
85. Klampfer L., Huang J., Sasazuki T., Shirasawa S., Augenlicht L. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Molecular Cancer Research 2003, 1:855-862.
86. Genin P., Morin P., Civas A. Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A. Journal of Virology 2003, 77:7113-7119.
87. Su R.C., Sivro A., Kimani J., Jaoko W., Plummer F.A., Ball T.B. Epigenetic control of IRF1 responses in HIV-exposed seronegative versus HIV-susceptible individuals. Blood 2011, 117:2649-2657.
88. Segre C.V., Chiocca S. Regulating the regulators: the post-translational code of class I HDAC1 and HDAC2. Journal of Biomedical and Biotechnology 2011, 2011:690848.
89. Lee J.L., Wang M.J., Chen J.Y. Acetylation and activation of STAT3 mediated by nuclear translocation of CD44. Journal of Cell Biology 2009, 185:949-957.
90. Shen L., Ciesielski M., Ramakrishnan S., Miles K.M., Ellis L., Sotomayor P., et al. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. PLoS One 2012, 7:e30815.
91. Khan O., La Thangue N.B. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunology and Cell Biology 2012, 90:85-94.
92. Nadiminty N., Lou W., Lee S.O., Lin X., Trump D.L., Gao A.C. Stat3 activation of NF-{kappa}B p100 processing involves CBP/p300-mediated acetylation. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:7264-7269.
93. Lee H., Zhang P., Herrmann A., Yang C., Xin H., Wang Z., et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:7765-7769.